Literature DB >> 17344569

How do you treat bleeding disorders with desmopressin?

Bülent Ozgönenel1, Madhvi Rajpurkar, Jeanne M Lusher.   

Abstract

Desmopressin is an analog of vasopressin that exerts a substantial haemostatic effect by inducing the release of von Willebrand factor from its storage sites in endothelial cells. It has proved useful in treating or preventing bleeding episodes in patients with von Willebrand disease, haemophilia A and platelet function defects. Its efficacy in achieving a satisfactory level of haemostasis has reduced the use of blood products to treat bleeding episodes. Clinicians need to become familiar with the use of this drug that has become a home medication for many patients with inherited bleeding disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17344569      PMCID: PMC2599976          DOI: 10.1136/pgmj.2006.052118

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  22 in total

1.  Evaluation of the PFA-100 system for monitoring desmopressin therapy in patients with type 1 von Willebrand's disease.

Authors:  Massimo Franchini; Giorgio Gandini; Franco Manzato; Giuseppe Lippi
Journal:  Haematologica       Date:  2002-06       Impact factor: 9.941

Review 2.  Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.

Authors:  Giancarlo Castaman; Augusto B Federici; Francesco Rodeghiero; Pier Mannuccio Mannucci
Journal:  Haematologica       Date:  2003-01       Impact factor: 9.941

Review 3.  Treatment of von Willebrand's Disease.

Authors:  Pier Mannuccio Mannucci
Journal:  N Engl J Med       Date:  2004-08-12       Impact factor: 91.245

4.  Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration.

Authors:  Michael Overman; Eric Brass
Journal:  Thromb Haemost       Date:  2004-10       Impact factor: 5.249

Review 5.  Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature.

Authors:  A Girolami; F Tezza; M Scapin; S Vettore; A Casonato
Journal:  J Thromb Thrombolysis       Date:  2006-04       Impact factor: 2.300

6.  Desmopressin and thrombosis.

Authors:  P M Mannucci; J M Lusher
Journal:  Lancet       Date:  1989-09-16       Impact factor: 79.321

Review 7.  Vasopressin agonists and antagonists.

Authors:  M Thibonnier
Journal:  Horm Res       Date:  1990

8.  DDAVP (desmopressin; 1-deamino-cys-8-D-arginine-vasopressin) treatment in children with haemophilia B.

Authors:  S Ehl; T Severin; A H Sutor
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

9.  Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study.

Authors:  Augusto B Federici; Claudine Mazurier; Erik Berntorp; Christine A Lee; Inge Scharrer; Jenny Goudemand; Stephan Lethagen; Ioana Nitu; Gerard Ludwig; Lysiane Hilbert; Pier M Mannucci
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

10.  DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.

Authors:  A I Warrier; J M Lusher
Journal:  J Pediatr       Date:  1983-02       Impact factor: 4.406

View more
  12 in total

1.  Antihemophilic factor [recombinant], formulated with sucrose.

Authors: 
Journal:  P T       Date:  2010-09

2.  An international survey to inform priorities for new guidelines on von Willebrand disease.

Authors:  Mohamad A Kalot; Mohammed Al-Khatib; Nathan T Connell; Veronica Flood; Romina Brignardello-Petersen; Paula James; Reem A Mustafa
Journal:  Haemophilia       Date:  2019-11-26       Impact factor: 4.287

Review 3.  Impact of drugs on venous thromboembolism risk in surgical patients.

Authors:  Alenka Premuš Marušič Kovačič; Martin Caprnda; Aleš Mrhar; Peter Kubatka; Igor Locatelli; Barbora Zolakova; Ludovit Gaspar; Robert Prosecky; Peter Kruzliak; Robert Staffa; Luis Rodrigo; Jozef Radonak; Danijel Petrovič
Journal:  Eur J Clin Pharmacol       Date:  2019-02-05       Impact factor: 2.953

Review 4.  Peptidomimetic therapeutics: scientific approaches and opportunities.

Authors:  Nir Qvit; Samuel J S Rubin; Travis J Urban; Daria Mochly-Rosen; Eric R Gross
Journal:  Drug Discov Today       Date:  2016-11-14       Impact factor: 7.851

5.  Desmopressin responsiveness by age in type 1 von Willebrand disease.

Authors:  Nicola Goldberg; Rosane Nisenbaum; Hong Song; David Lillicrap; Jerome Teitel; Paula James; Michelle Sholzberg
Journal:  Res Pract Thromb Haemost       Date:  2020-05-30

Review 6.  Effect of Desmopressin on Platelet Dysfunction During Antiplatelet Therapy: A Systematic Review.

Authors:  Lise Kjær Andersen; Anne-Mette Hvas; Christine Lodberg Hvas
Journal:  Neurocrit Care       Date:  2020-08-04       Impact factor: 3.210

7.  Vasopressin: Its current role in anesthetic practice.

Authors:  Jayanta K Mitra; Jayeeta Roy; Saikat Sengupta
Journal:  Indian J Crit Care Med       Date:  2011-04

8.  Early recognition of intraventricular hemorrhage in the setting of thrombocytosis in the emergency department.

Authors:  Marvinia Charles; Romy Fontoura; Gregory Sugalski
Journal:  Open Access Emerg Med       Date:  2016-05-12

Review 9.  Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories.

Authors:  A Magnette; M Chatelain; B Chatelain; H Ten Cate; F Mullier
Journal:  Thromb J       Date:  2016-12-12

10.  Gastrointestinal Bleeding from Metastatic Prostate Adenocarcinoma to the Stomach.

Authors:  Andree Koop; Bhaumik Brauhmbhatt; Jason Lewis; Michele D Lewis
Journal:  ACG Case Rep J       Date:  2017-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.